Marcy l’Étoile (France), April 9th, 2024 – bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2024.
- Strong momentum with +10% organic sales growth in the first quarter
- Performance driven by remarkable growth of BIOFIRE®1 non-respiratory panels at +19%, BIOFIRE® respiratory panels at +12% and microbiology at +9%
- Continuation of the successful ramp-up of SPOTFIRE®2 with 400 new instruments installed in the quarter and €20m of sales
- bioMérieux confirms its 2024 guidance for sales and operating profit, targeting an organic sales growth between +6% and +8%, and a contributive operating income before non-recurring items growing at least by +10% at constant exchange rates
Pierre Boulud, Chief Executive Officer, said: “With +10% sales growth in the first quarter of 2024, bioMérieux delivered an extremely strong performance, demonstrating the relevance of its solutions to meet medical needs. The +14% growth in BIOFIRE® panels sales and the promising launch of the new SPOTFIRE® illustrate the continuous development of the syndromic approach. In addition, the microbiology franchise continued to perform remarkably well. This strong quarterly performance represents a solid cornerstone to reach our 2024 financial objectives.”
Read the full press release
- Filename
- PR_bioMérieux_Business_Review_Q1_2024_20240409.pdf
- Size
- 263 KB
- Format
- application/pdf